These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 20172739)

  • 1. The role of invariant NKT cells at the interface of innate and adaptive immunity.
    Cerundolo V; Kronenberg M
    Semin Immunol; 2010 Apr; 22(2):59-60. PubMed ID: 20172739
    [No Abstract]   [Full Text] [Related]  

  • 2. Lipid and glycolipid antigens of CD1d-restricted natural killer T cells.
    Venkataswamy MM; Porcelli SA
    Semin Immunol; 2010 Apr; 22(2):68-78. PubMed ID: 19945296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-edged sword: the role of NKT cells in malaria and HIV infection and immunity.
    Vasan S; Tsuji M
    Semin Immunol; 2010 Apr; 22(2):87-96. PubMed ID: 19962909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Harnessing invariant NKT cells in vaccination strategies.
    Cerundolo V; Silk JD; Masri SH; Salio M
    Nat Rev Immunol; 2009 Jan; 9(1):28-38. PubMed ID: 19079136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing NKT cell ligands as vaccine adjuvants.
    Carreño LJ; Kharkwal SS; Porcelli SA
    Immunotherapy; 2014; 6(3):309-20. PubMed ID: 24762075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recognition of CD1d-restricted antigens by natural killer T cells.
    Rossjohn J; Pellicci DG; Patel O; Gapin L; Godfrey DI
    Nat Rev Immunol; 2012 Dec; 12(12):845-57. PubMed ID: 23154222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical development of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant.
    Padte NN; Li X; Tsuji M; Vasan S
    Clin Immunol; 2011 Aug; 140(2):142-51. PubMed ID: 21185784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Navigating the Role of CD1d/Invariant Natural Killer T-cell/Glycolipid Immune Axis in Multiple Myeloma Evolution: Therapeutic Implications.
    Papoutselis M; Spanoudakis E
    Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):358-365. PubMed ID: 32234294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Recognition of CD1d/glycolipid antigen complex by NKT cells and mechanisms in immune regulation].
    Watarai H; Tashiro T; Chiba T; Taniguchi M
    Tanpakushitsu Kakusan Koso; 2008 Sep; 53(12 Suppl):1584-9. PubMed ID: 21089371
    [No Abstract]   [Full Text] [Related]  

  • 10. CD1d and natural killer T cells in immunity to Mycobacterium tuberculosis.
    Arora P; Foster EL; Porcelli SA
    Adv Exp Med Biol; 2013; 783():199-223. PubMed ID: 23468111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complementary approaches to study NKT cells in cancer.
    Berzofsky JA; Olkhanud PB; Terabe M
    Methods Enzymol; 2020; 631():371-389. PubMed ID: 31948558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities.
    Wu L; Gabriel CL; Parekh VV; Van Kaer L
    Tissue Antigens; 2009 Jun; 73(6):535-45. PubMed ID: 19392798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carbohydrate specificity of the recognition of diverse glycolipids by natural killer T cells.
    Zajonc DM; Kronenberg M
    Immunol Rev; 2009 Jul; 230(1):188-200. PubMed ID: 19594637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How invariant natural killer T cells respond to infection by recognizing microbial or endogenous lipid antigens.
    Brigl M; Brenner MB
    Semin Immunol; 2010 Apr; 22(2):79-86. PubMed ID: 19948416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural killer T cells in lipoprotein metabolism and atherosclerosis.
    Getz GS; Vanderlaan PA; Reardon CA
    Thromb Haemost; 2011 Nov; 106(5):814-9. PubMed ID: 21946866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Harnessing CD1d-restricted T cells toward antitumor immunity in humans.
    Neparidze N; Dhodapkar MV
    Ann N Y Acad Sci; 2009 Sep; 1174():61-7. PubMed ID: 19769737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Scavenger receptors target glycolipids for natural killer T cell activation.
    Freigang S; Landais E; Zadorozhny V; Kain L; Yoshida K; Liu Y; Deng S; Palinski W; Savage PB; Bendelac A; Teyton L
    J Clin Invest; 2012 Nov; 122(11):3943-54. PubMed ID: 23064364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Invariant natural killer T cells as sensors and managers of inflammation.
    Van Kaer L; Parekh VV; Wu L
    Trends Immunol; 2013 Feb; 34(2):50-8. PubMed ID: 23017731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functions of CD1d-Restricted Invariant Natural Killer T Cells in Antimicrobial Immunity and Potential Applications for Infection Control.
    Kinjo Y; Takatsuka S; Kitano N; Kawakubo S; Abe M; Ueno K; Miyazaki Y
    Front Immunol; 2018; 9():1266. PubMed ID: 29928278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant.
    Li X; Fujio M; Imamura M; Wu D; Vasan S; Wong CH; Ho DD; Tsuji M
    Proc Natl Acad Sci U S A; 2010 Jul; 107(29):13010-5. PubMed ID: 20616071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.